Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures.


Journal

Epilepsia open
ISSN: 2470-9239
Titre abrégé: Epilepsia Open
Pays: United States
ID NLM: 101692036

Informations de publication

Date de publication:
12 2022
Historique:
received: 28 03 2022
accepted: 28 07 2022
pubmed: 1 8 2022
medline: 3 12 2022
entrez: 31 7 2022
Statut: ppublish

Résumé

Eslicarbazepine acetate (ESL) is a once-daily (QD), oral anti-seizure medication for the treatment of focal (partial-onset) seizures. Here, we evaluate risk factors for the development of psychiatric treatment-emergent adverse events (TEAEs) in clinical trials of adjunctive ESL in adults with focal seizures. This post-hoc analysis evaluated data pooled from three Phase III, randomized, double-blind, placebo-controlled trials (BIA-2093-301, -302, -304). After an 8-week baseline period, patients were randomized equally to receive placebo, ESL 400 mg (not reported here), 800 mg, or 1200 mg QD (up to 2-week titration; 12-week maintenance; optional open-label extension [OLE]). Incidences of psychiatric TEAEs were evaluated according to three separate criteria: medical history of psychiatric disorders (yes/no); baseline use of psychotropic drugs (yes/no); Montgomery-Åsberg Depression Rating Scale (MADRS) score at baseline (0-6: normal; 7-19: mild depression; 20-34: moderate depression). The analysis populations comprised 1251 patients for the controlled study period and 1137 patients for the 1-year OLE. Psychiatric TEAE incidence was similar between patients taking ESL and placebo in the controlled and OLE study periods and was not related to ESL dose. Psychiatric TEAEs generally occurred more frequently in patients with a medical history of psychiatric disorders, using psychotropic drugs, or with depressive symptoms than in those without a history, not using psychotropic drugs, or with no depressive symptoms. Depression and anxiety were the most frequently reported psychiatric TEAEs. Overall, in clinical trials of ESL in adults with focal seizures, incidences of psychiatric events were not statistically different between patients taking ESL and placebo, were not related to ESL dose, and generally occurred more frequently in patients with baseline psychiatric symptoms or a history of psychiatric disorders. Long-term exposure to ESL was not associated with a marked increase in the incidence of psychiatric TEAEs.

Identifiants

pubmed: 35908275
doi: 10.1002/epi4.12635
pmc: PMC9712463
doi:

Substances chimiques

Anticonvulsants 0
Dibenzazepines 0
eslicarbazepine acetate BEA68ZVB2K

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

616-632

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Informations de copyright

© 2022 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.

Références

Nat Rev Neurol. 2016 Feb;12(2):106-16
pubmed: 26782334
Epilepsy Behav. 2017 Jul;72:127-134
pubmed: 28575761
Epilepsia Open. 2022 Dec;7(4):616-632
pubmed: 35908275
Curr Treat Options Neurol. 2017 Oct 19;19(12):44
pubmed: 29046989
Transl Psychiatry. 2018 Aug 16;8(1):157
pubmed: 30115911
Trends Neurosci. 2012 Jan;35(1):36-46
pubmed: 22217451
Geriatr Psychol Neuropsychiatr Vieil. 2018 Jun 1;16(2):181-188
pubmed: 29877186
Pharmacol Rep. 2016 Oct;68(5):1084-92
pubmed: 27634589
Epilepsia. 2009 Mar;50(3):454-63
pubmed: 19243424
Seizure. 2017 Jul;49:79-82
pubmed: 28532711
Epilepsy Behav. 2019 Nov;100(Pt A):106439
pubmed: 31574428
Expert Opin Pharmacother. 2019 Jan;20(1):41-45
pubmed: 30428279
Epilepsy Behav. 2020 Jan;102:106669
pubmed: 31785486
Drugs Aging. 2008;25(11):955-62
pubmed: 18947263
World J Biol Psychiatry. 2018 Feb;19(1):2-58
pubmed: 29098925
Epilepsy Res. 2010 May;89(2-3):278-85
pubmed: 20299189
JAMA Neurol. 2019 Apr 1;76(4):440-446
pubmed: 30688969
Lancet Neurol. 2012 Sep;11(9):792-802
pubmed: 22832500
Am J Health Syst Pharm. 2009 Mar 15;66(6):541-61
pubmed: 19265183
Epilepsia. 2017 Jul;58(7):1123-1130
pubmed: 28464309
Epilepsy Behav. 2011 May;21(1):1-11
pubmed: 21498130
Epilepsy Behav. 2018 May;82:119-127
pubmed: 29604484
Epilepsia. 2015 Feb;56(2):244-53
pubmed: 25528898

Auteurs

Hamada Altalib (H)

Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.

Todd Grinnell (T)

Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.

David Cantu (D)

Sunovion Pharmaceuticals Inc., Fort Lee, New Jersey, USA.

Fábio Ikedo (F)

Pharmacovigilance Compliance, BIAL - Portela & Cª, S.A., São Mamede do Coronado, Portugal.

Mariana Vieira (M)

Pharmacovigilance Compliance, BIAL - Portela & Cª, S.A., São Mamede do Coronado, Portugal.

Yi Zhang (Y)

Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.

David Blum (D)

Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH